Tempest Therapeutics, Inc. TPST NASDAQ

Tempest Therapeutics, Inc. (TPST) generated $-24.5M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $0.00, free cash flow was $-24.5M.

Cash conversion ratio was 6.09x, indicating earnings are backed by cash.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 6.09x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 51/100 with 2/7 criteria passed.